Senior HEOR Consultant

Successfully completed various projects

Over 15 years of experience as a consultant in the area of HEOR

Experienced in a wide range of pharmaceutical products

Created cost-utility models and budget impact models

Interim lead team of clinicians and health economist to implement projects

Interim lead projects from proposal to implementation for partnerships with consultancy companies

Created value proposition and strategy

Contributed to commercialization strategy

Created CEM and BIM economic models to build up body of economic evidence

Commissioned multiple projects to build clinical and economic evidence including a time-trade-off project

Coached junior members of HEOR and market access teams in headquarter and affiliates worldwide

Provided proposals

Successfully created seven cost-effectiveness and budget impact models/model adaptation in Excel, VBA, and SQL

Implemented full Markov Models, Semi-Markov Models – using area-under-the-curve analysis, decision trees, PSA and DSA

Managed relationship with clinical experts, pharmaceutical clients, and other economists in the project team

Developed a case for change in local health economies, presenting areas for improvement with evidence from outcome research (e.g., disease prevalence, hospital infection rates, bed days)

Created modelling of financial flow and impact; advised on options and their potential impac

Conducted health economics training workshops for medical affairs, marketing, clinical development, and public affairs teams to enhance competencies and optimize market access awareness

Managed the evaluation, development, definition and implementation of economic value and pricing strategies for the product portfolio

Collaborated across lifecycle and international business teams to optimize market strategies and reimbursement/pricing for new products

Interim lead cross-functional group on health economics, pricing, and market access evaluation for inhouse due diligence on potential in-licensed product

Provided counsel and strategic advice on a few policy and market access issues - current and emerging

Project management responsibilities

Screened orphan disease to discover unmet need and areas of high innovation

Calculated disease burden and unmet needs to evaluate potential partnerships with pharmaceutical or medical device companies lacking business development infrastructure

Strong focus on strategic insights along with project management responsibilities

Advised on creation of global and localized value dossiers, reimbursement dossiers, HTA submission

Interviewed key opinion leaders

Initiated observational & retrospective studies

Lead team to develop due diligence projects for private equity acquisitions